Paper26323629
The Intestinal Microbiota in Inflammatory Bowel Disease.
Becker C and 2 others. ILAR J, 2015. Cited by 140 papers, by iCite.
Cite this record
ConductScience Library. The Intestinal Microbiota in Inflammatory Bowel Disease. Papers, record 26323629. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26323629
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Gastrointestinal Microbiome | Major topic |
| Animals | |
| Colitis, Ulcerative | |
| Crohn Disease | |
| Humans | |
| Inflammatory Bowel Diseases | |
| Models, Animal |
Source PubMed
Cited by96
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 140 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41931118 | Microbiota-driven mechanisms in multisystem diseases: integrative evidence across cardiovascular, metabolic, neurological and autoimmune disorders. | Antonie Van Leeuwenhoek | 2026 | https://conductscience.org/library/papers/41931118 | PubMed |
| 41859469 | Colonic biopsy-associated microbial signatures are predictive of response to anti-TNFα biological therapy in Crohn's disease. | Front Cell Infect Microbiol | 2026 | https://conductscience.org/library/papers/41859469 | PubMed |
| 40895645 | Ingestible Electronics for Diagnostics and Therapy. | Nat Rev Mater | 2019 | https://conductscience.org/library/papers/40895645 | PubMed |
| 40003718 | Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis; A Placebo Randomized Controlled Trial. | Life (Basel) | 2025 | https://conductscience.org/library/papers/40003718 | PubMed |
| 39351093 | LC-MS/MS-based metabolomics and proteomics reveal the intervention of Kangnian decoction on the postoperative intestinal adhesion of rats. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/39351093 | PubMed |
| 39295907 | Microbial gut dysbiosis induced by xenobiotics in model organisms and the relevance of experimental criteria: a minireview. | Gut Microbiome (Camb) | 2023 | https://conductscience.org/library/papers/39295907 | PubMed |
| 39155343 | Bacteroides fragilis in saliva: investigating links with ulcerative colitis. | Braz J Microbiol | 2024 | https://conductscience.org/library/papers/39155343 | PubMed |
| 39065768 | Impact of Microbiota and Metabolites on Intestinal Integrity and Inflammation in Severe Obesity. | Pharmaceuticals (Basel) | 2024 | https://conductscience.org/library/papers/39065768 | PubMed |
| 39063111 | Flavonoids-Enriched Vegetal Extract Prevents the Activation of NFκB Downstream Mechanisms in a Bowel Disease In Vitro Model. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39063111 | PubMed |
| 39051416 | Blood Microbiota and Its Products: Mechanisms of Interference with Host Cells and Clinical Outcomes. | Hematol Rep | 2024 | https://conductscience.org/library/papers/39051416 | PubMed |
| 38917002 | The epithelial C15ORF48/miR-147-NDUFA4 axis is an essential regulator of gut inflammation, energy metabolism, and the microbiome. | Proc Natl Acad Sci U S A | 2024 | https://conductscience.org/library/papers/38917002 | PubMed |
| 38529406 | The epithelium takes the stage in asthma and inflammatory bowel diseases. | Front Cell Dev Biol | 2024 | https://conductscience.org/library/papers/38529406 | PubMed |
| 37873040 | Favipiravir Protects Enterocytes From Cell Death After Inflammatory Storm. | Cureus | 2023 | https://conductscience.org/library/papers/37873040 | PubMed |
| 37851313 | Gut-Brain Axis a Key Player to Control Gut Dysbiosis in Neurological Diseases. | Mol Neurobiol | 2024 | https://conductscience.org/library/papers/37851313 | PubMed |
| 37736959 | Health Benefits of Montmorency Tart Cherry Juice Supplementation in Adults with Mild to Moderate Ulcerative Colitis: A Protocol for a Placebo Randomized Controlled Trial. | Methods Protoc | 2023 | https://conductscience.org/library/papers/37736959 | PubMed |
| 37695333 | Effect of chronic low-dose treatment with chitooligosaccharides on microbial dysbiosis and inflammation associated chronic ulcerative colitis in Balb/c mice. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/37695333 | PubMed |
| 37601990 | Diet as an Optional Treatment in Adults With Inflammatory Bowel Disease: A Systematic Review of the Literature. | Cureus | 2023 | https://conductscience.org/library/papers/37601990 | PubMed |
| 37431863 | Gut microbiota-related bile acid metabolism-FXR/TGR5 axis impacts the response to anti-α4β7-integrin therapy in humanized mice with colitis. | Gut Microbes | 2023 | https://conductscience.org/library/papers/37431863 | PubMed |
| 37361202 | The gut dysbiosis-cancer axis: illuminating novel insights and implications for clinical practice. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37361202 | PubMed |
| 37197397 | Precision medicine and drug optimization in adult inflammatory bowel disease patients. | Ther Adv Gastroenterol | 2023 | https://conductscience.org/library/papers/37197397 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26323629
GET https://conductscience.org/api/papers/v1/26323629/cited_by?page=2